Evidence map›Paper›PMID 40267877›Full record

ArticleEuropean journal of medicinal chemistry2025

Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci.

Andrea Ammara, Simone Giovannuzzi, Alessandro Bonardi, Nader S Abutaleb, Ahmed A Abouelkhair, Daniel P Flaherty, Mohamed N Seleem, Clemente Capasso, Paola Gratteri, Alessio Nocentini and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Antimicrobial Activity of 1,3,4-Thiadiazole Derivatives.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea AmmaraNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy; NEUROFARBA Department, Laboratory of Molecular Modeling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.
Simone GiovannuzziNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy. Electronic address: simone.giovannuzzi@unifi.it.
Alessandro BonardiNEUROFARBA Department, Laboratory of Molecular Modeling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.
Nader S AbutalebDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA; Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Ahmed A AbouelkhairDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA; Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Daniel P FlahertyDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA; Purdue Institute for Drug Discovery, West Lafayette, IN, USA; Purdue Institute of Inflammation, Immunology and Infectious Disease, West Lafayette, IN, USA.
Mohamed N SeleemDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA; Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Clemente CapassoIstituto di Bioscienze e Biorisorse, CNR, 80131, Naples, Italy.
Paola GratteriNEUROFARBA Department, Laboratory of Molecular Modeling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.
Alessio NocentiniNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy. Electronic address: alessio.nocentini@unifi.it.
Claudiu T SupuranNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy.

Funding

Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococciR01AI148523 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Daniel Patrick Flaherty, Mohamed Seleem · 2019 to 2026
$4.2M
Development of novel anti-Neisseria gonorrhoeae therapeutic agentsR01AI153264 · NIAID · PURDUE UNIVERSITY · PI FLAHERTY, DANIEL PATRICK · 2022 to 2025
$3.1M
NIAID NIH HHS R01 AI148523NIAID NIH HHS R01 AI153264
6 · The paper itself

Abstract

The rise of vancomycin-resistant enterococci (VRE) as a leading cause of hospital-acquired infections underscores the urgent need for new treatment strategies. In fact, resistance has developed not only to vancomycin but also to other clinically used agents, such as daptomycin and linezolid. We propose a novel drug design approach merging tedizolid, a second-generation oxazolidinone used as an unapproved salvage therapy in clinical settings, with carbonic anhydrase inhibitors (CAIs) recently validated as functioning decolonization agents. These sulfonamide derivatives showed potent inhibition of the carbonic anhydrases from Enterococcus faecium, with K

Indexed as

Anti-Bacterial AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesDrug DesignEnterococcus faeciumOxazolidinonesVancomycin-Resistant EnterococciDose-Response Relationship, DrugEnterococcus faecalisMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesOxazolidinonesBacterial resistanceCarbonic anhydrase inhibitionoxazolidinoneTedizolidVRE infections

Identifiers

PMID40267877
PMCPMC12186203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.